^
    Back
    Association details:
    Biomarker:RET mutation
    Cancer:Thyroid Gland Anaplastic Carcinoma
    Drug:Retevmo (selpercatinib) (RET inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Selpercatinib (RET mutation-positive) was added as a preferred treatment option.
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Thyroid Gland Medullary Carcinoma)
    New
    Title:

    The China NMPA Approves Selpercatinib for the Treatment of Patients with RET-driven Lung and Thyroid Cancers

    Excerpt:
    Innovent Biologics, Inc...is pleased to see that the National Medical Products Administration (NMPA) of China has approved the New Drug Application (NDA) for selpercatinib (40mg & 80mg capsules) for...adult and pediatric patients 12 years of age and older with advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation who require systemic therapy...